Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop traditional diet and exercise programs.
Research printed in a leading health publication demonstrates that while obese people frequently drop a large proportion of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using such drugs must be cognizant of the risk of quick weight regain when the medication ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment mass in about one and a half years.
Weighing Approaches
The study, which examined dozens of studies involving thousands of patients, compared the effects of the injectable medications with older methods.
Scientists note that people who shed pounds through lifestyle changes alone typically experience a slower creep back—around 100 grams monthly—once they finish.
Explaining the Fast Regain
Experts suggest the mode of action of the jabs is key to understanding the amplified rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals say that, considering the likelihood of relapse, the treatment should be considered ongoing.
This opinion is supported by drug manufacturers, who note that the findings "emphasize the chronic character of obesity," comparing it to managing conditions like hypertension.
User Accounts
Individuals who have come off the jabs describe a intense resurgence of hunger.
"It was like a trigger activating and you become starving," said an individual.
The struggle is exacerbated if patients have not developed sustainable lifestyle or habit changes during therapy.
Significant Use
Recent estimates suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated lifestyle changes.
